Last updated: February 20, 2026
What is AVACLYR?
AVACLYR is a investigational drug developed by AbbVie, designed as a potential therapeutic for the treatment of non-alcoholic steatohepatitis (NASH). It is currently in Phase 2 clinical trials and has not received regulatory approval. The drug's mechanism targets metabolic pathways involved in NASH and fibrosis progression.
Market Potential
NASH affects approximately 3-6% of the global population, with an estimate of 50 million affected individuals in major markets. The global NASH therapeutics market was valued at $1.9 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 35% through 2030.
| Attribute |
Data Points |
| Prevalence |
3-6% worldwide; 50 million in major markets |
| Market Size (2022) |
$1.9 billion |
| Forecasted CAGR |
35% (2023-2030) |
| Estimated 2030 Market Size |
$14 - $20 billion |
Signs of unmet need include limited approved therapies; currently, no drugs have received FDA approval for NASH. Existing treatments tackle related conditions like type 2 diabetes or obesity but lack specific efficacy data for NASH fibrosis.
Clinical Development and Regulatory Status
AVACLYR is in Phase 2. Key trial results are expected in late 2023 or early 2024. In the Phase 2 trial, primary endpoints include improvements in liver histology and fibrosis scores.
| Trial Phase |
Status |
Key Outcomes |
Estimated Completion |
Regulatory Milestone |
| Phase 2 |
Ongoing |
Liver histology improvements |
Late 2023 |
Possibility of Breakthrough Therapy designation or accelerated review if positive |
Regulatory pathways include future potential for accelerated approval in the U.S., given the unmet need and serious disease burden.
Competitive Landscape
Major competitors include companies developing FXR agonists, PPAR agonists, and anti-fibrotic agents:
- Intercept Pharmaceuticals: Obeticholic acid (OCA), Phase 3
- Genfit: Elafibranor, Phase 3
- Gilead Sciences: GS-0976, Phase 2
Market entry hinges on demonstrating significant efficacy and safety benefits over existing candidates.
Financial Profile and Investment Considerations
AbbVie's R&D expenditure for NASH-related drugs is approximately $300 million annually. For AVACLYR's development to reach approval, an estimated investment of $500 million-$1 billion will be necessary over the next 4-5 years, covering clinical trials and regulatory processes.
| Investment Stage |
Estimated Cost |
Timeline |
Key Risks |
| Phase 2 completion |
$50 million |
By late 2023 |
Failed efficacy or safety signals |
| Phase 3 trials |
$400-$700 million |
2024-2027 |
High failure risk, competitive landscape |
| Regulatory approval |
$50-$100 million |
2028 |
Delays, safety concerns |
Commercial adoption depends on demonstrating superiority or non-inferiority versus competitors and overcoming pricing pressures due to generic generic competitors.
Risk Factors
- Regulatory risks: Clinical efficacy must be demonstrated conclusively; failure leads to sunk costs.
- Market risks: Slow adoption due to competition, pricing, or reimbursement issues.
- Development risks: Unexpected adverse effects could lead to trial halts.
- Intellectual property: Patent challenges or expirations could diminish valuation.
Investment Outlook
AVACLYR presents high-risk, high-reward potential. Its market size and unmet need support long-term value, but clinical and regulatory milestones are critical. Investors should weigh AbbVie's financial capacity to sustain a multi-year development program against potential returns if AVACLYR progresses successfully.
Key Takeaways
- AVACLYR is in early development stage, targeting a large unmet medical need.
- Market size for NASH therapeutics could reach $20 billion by 2030.
- Probable clinical milestones in late 2023–2024 influence valuation.
- Major competitors are also advancing their candidates, intensifying the race.
- Investment involves high risk with potential for significant upside upon approval.
FAQs
Q1: When will clinical trials for AVACLYR likely conclude?
A1: Primary endpoint data from Phase 2 are expected late 2023 to early 2024.
Q2: How does AVACLYR compare to its competitors?
A2: Confirmed efficacy and safety are pending; competing drugs such as OCA and elafibranor are in Phase 3 or close.
Q3: What are the main regulatory considerations?
A3: Possibility of accelerated approval pathways if results show significant benefits over existing therapies.
Q4: What is the estimated investment needed for bringing AVACLYR to approval?
A4: $500 million to $1 billion over roughly 4-5 years.
Q5: What are the primary market risks?
A5: Delayed or failed trials, regulatory setbacks, aggressive competition, reimbursement challenges.
References
[1] MarketsandMarkets. (2022). NASH therapeutics market forecast.
[2] AbbVie. (2023). Annual R&D expenditure report.
[3] U.S. Food and Drug Administration. (2022). Regulatory pathways for NASH drugs.
[4] GlobalData. (2022). Competitive landscape in NASH therapeutics.
